Mani (7730) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
13 Jun, 2025Executive summary
Achieved record highs in net sales, operating income, ordinary income, and net income for the third consecutive year in FY2024, driven by strong overseas demand and favorable foreign exchange rates.
All product segments and regions saw sales growth, with Asia (especially China and India) and North America as key contributors.
FY2024 results exceeded forecasts, and the company projects continued growth for FY2025 despite a strong yen environment.
Financial highlights
FY2024 net sales rose 16.4% year-over-year to ¥28,513 million; operating income up 15.8% to ¥8,392 million.
Net income increased 5.6% to ¥6,286 million; EBITDA reached ¥10,062 million.
Gross margin remained stable at 62.8%; operating margin at 29.4%.
Overseas sales ratio reached 85.2%.
Outlook and guidance
FY2025 forecasts: net sales of ¥30,200 million (+5.9%), operating income of ¥8,900 million (+6.1%), net income of ¥6,350 million (+1.0%).
Assumed exchange rate for FY2025 is ¥136/USD, reflecting a stronger yen.
Upfront investments in marketing and personnel planned for Southeast Asia and North America.
Annual dividend forecast maintained at ¥39 per share.
Latest events from Mani
- Record 1Q sales and profit driven by China recovery, Asian demand, and European expansion.7730
Q1 202614 Jan 2026 - Surgical and eyeless needle growth offset dental decline, supporting ambitious FY2029 targets.7730
Q1 202510 Jan 2026 - Surgical and Eyeless Needle growth offset China dental recall; outlook and dividends unchanged.7730
Q2 202524 Dec 2025 - Net income fell 17.8% despite higher sales, with strong FY2026 recovery and dividend growth forecast.7730
Q4 20258 Oct 2025 - Profit fell on higher costs and a China recall despite sales growth in key segments.7730
Q3 20259 Jul 2025 - Strong 3Q growth driven by overseas demand and yen depreciation, with global expansion ongoing.7730
Q3 202413 Jun 2025